Pharvaris N.V.(PHVS) - 2022 Q4 - Annual Report

Exhibit 99.1 Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Zug, Switzerland, April 5, 2023 – Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a business update. "Our first in-patient data readout of deucrictibant in people living with HAE ...